BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, Gammaldi R, Maglio A, Sellitto C, Vitale C, Serio B, Cuffa B, Borrelli A, Vecchione C, Filippelli A, Selleri C. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. Front Pharmacol 2020;11:857. [PMID: 32581810 DOI: 10.3389/fphar.2020.00857] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). International Immunopharmacology 2022;105:108536. [DOI: 10.1016/j.intimp.2022.108536] [Reference Citation Analysis]
2 Kumar V. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. Int Immunopharmacol 2020;88:106980. [PMID: 33182073 DOI: 10.1016/j.intimp.2020.106980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
3 Kurtovic L, Beeson JG. Complement Factors in COVID-19 Therapeutics and Vaccines. Trends Immunol 2021;42:94-103. [PMID: 33402318 DOI: 10.1016/j.it.2020.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol 2020;220:108598. [PMID: 32961333 DOI: 10.1016/j.clim.2020.108598] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 34.0] [Reference Citation Analysis]
5 Schmidt C, Weißmüller S, Bohländer F, Germer M, König M, Staus A, Wartenberg-Demand A, Heinz CC, Schüttrumpf J. The Dual Role of a Polyvalent IgM/IgA-Enriched Immunoglobulin Preparation in Activating and Inhibiting the Complement System. Biomedicines 2021;9:817. [PMID: 34356880 DOI: 10.3390/biomedicines9070817] [Reference Citation Analysis]
6 Das A, Rana S. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19. Comput Biol Chem 2021;92:107482. [PMID: 33845430 DOI: 10.1016/j.compbiolchem.2021.107482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Desvaux E, Hamon A, Hubert S, Boudjeniba C, Chassagnol B, Swindle J, Aussy A, Laigle L, Laplume J, Soret P, Jean-François P, Dupin-Roger I, Guedj M, Moingeon P. Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19. PLoS One 2021;16:e0254374. [PMID: 34293006 DOI: 10.1371/journal.pone.0254374] [Reference Citation Analysis]
8 Genthon A, Chiarabini T, Baylac P, Valin N, Urbina T, Pacanowski J, Mekinian A, Brissot E, M 'Hammedi-Bouzina F, Lapusan S, Mohty M, Lacombe K, Ingiliz P. Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy. Leuk Lymphoma 2021;62:1502-5. [PMID: 33416421 DOI: 10.1080/10428194.2020.1869963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Valenzuela-Almada MO, Putman MS, Duarte-García A. The protective effect of rheumatic disease agents in COVID-19. Best Pract Res Clin Rheumatol 2021;35:101659. [PMID: 33526326 DOI: 10.1016/j.berh.2021.101659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
11 Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients. TH Open 2021;5:e89-e103. [PMID: 33709050 DOI: 10.1055/s-0041-1723784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Amere Subbarao S. Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. Inflammopharmacology 2021;29:343-66. [PMID: 33723711 DOI: 10.1007/s10787-021-00796-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Alunno A, Najm A, Mariette X, De Marco G, Emmel J, Mason L, McGonagle DG, Machado PM. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Ann Rheum Dis 2021:annrheumdis-2020-219725. [PMID: 33589438 DOI: 10.1136/annrheumdis-2020-219725] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
14 Guo H, Yang R, He J, Chen K, Yang W, Liu J, Xiao K, Li H. Edaravone combined with dexamethasone exhibits synergic effects on attenuating smoke-induced inhalation lung injury in rats. Biomed Pharmacother 2021;141:111894. [PMID: 34225014 DOI: 10.1016/j.biopha.2021.111894] [Reference Citation Analysis]
15 Gavriilaki M, Kimiskidis VK, Gavriilaki E. Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Pharmaceuticals (Basel) 2020;13:E341. [PMID: 33114553 DOI: 10.3390/ph13110341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chen P, Tang Y, He W, Yang R, Lan Z, Chen R, Zhang P, Yokota S. Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome. Mediators of Inflammation 2022;2022:1-17. [DOI: 10.1155/2022/7137900] [Reference Citation Analysis]
17 Felsenstein S, Reiff AO. A hitchhiker's guide through the COVID-19 galaxy. Clin Immunol 2021;232:108849. [PMID: 34563684 DOI: 10.1016/j.clim.2021.108849] [Reference Citation Analysis]
18 Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel) 2021;14:738. [PMID: 34451835 DOI: 10.3390/ph14080738] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
19 Synowiec A, Szczepański A, Barreto-Duran E, Lie LK, Pyrc K. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. Clin Microbiol Rev 2021;34:e00133-20. [PMID: 33441314 DOI: 10.1128/CMR.00133-20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
20 Ackermann M, Anders HJ, Bilyy R, Bowlin GL, Daniel C, De Lorenzo R, Egeblad M, Henneck T, Hidalgo A, Hoffmann M, Hohberger B, Kanthi Y, Kaplan MJ, Knight JS, Knopf J, Kolaczkowska E, Kubes P, Leppkes M, Mahajan A, Manfredi AA, Maueröder C, Maugeri N, Mitroulis I, Muñoz LE, Narasaraju T, Naschberger E, Neeli I, Ng LG, Radic MZ, Ritis K, Rovere-Querini P, Schapher M, Schauer C, Simon HU, Singh J, Skendros P, Stark K, Stürzl M, van der Vlag J, Vandenabeele P, Vitkov L, von Köckritz-Blickwede M, Yanginlar C, Yousefi S, Zarbock A, Schett G, Herrmann M. Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ 2021. [PMID: 34031543 DOI: 10.1038/s41418-021-00805-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T, Piazza O, Filippelli A. Experimental Pharmacotherapy for COVID-19: The Latest Advances. J Exp Pharmacol 2021;13:1-13. [PMID: 33442304 DOI: 10.2147/JEP.S255209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
22 Giudice V, Vecchione C, Selleri C. Cardiotoxicity of Novel Targeted Hematological Therapies. Life (Basel) 2020;10:E344. [PMID: 33322351 DOI: 10.3390/life10120344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, Reniarti L, Roesli RMA. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. Clin Epidemiol Glob Health 2021;11:100755. [PMID: 33969237 DOI: 10.1016/j.cegh.2021.100755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Silva TF, Tomiotto-Pellissier F, Sanfelice RA, Gonçalves MD, da Silva Bortoleti BT, Detoni MB, Rodrigues ACJ, Carloto ACM, Concato VM, Siqueira EDS, Costa IN, Pavanelli WR, Conchon-Costa I, Miranda-Sapla MM. A 21st Century Evil: Immunopathology and New Therapies of COVID-19. Front Immunol 2020;11:562264. [PMID: 33193331 DOI: 10.3389/fimmu.2020.562264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Hejaz HA. Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19). Avicenna J Med 2020;10:135-62. [PMID: 33437687 DOI: 10.4103/ajm.ajm_171_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Richardson E, García-Bernal D, Calabretta E, Jara R, Palomo M, Baron RM, Yanik G, Fareed J, Vlodavsky I, Iacobelli M, Díaz-Ricart M, Richardson PG, Carlo-Stella C, Moraleda JM. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin Ther Targets 2021;:1-11. [PMID: 34167431 DOI: 10.1080/14728222.2021.1944101] [Reference Citation Analysis]
27 Favaloro EJ, Henry BM, Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin Thromb Hemost 2021;47:400-18. [PMID: 33893632 DOI: 10.1055/s-0041-1727282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
28 Marcuzzi A, Rimondi E, Melloni E, Gonelli A, Grasso AG, Barbi E, Maximova N. Early Use of Low-Dose Ruxolitinib: A Promising Strategy for the Treatment of Acute and Chronic GVHD. Pharmaceuticals 2022;15:374. [DOI: 10.3390/ph15030374] [Reference Citation Analysis]
29 Dalakas MC. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev Clin Immunol 2022;:1-11. [PMID: 35323101 DOI: 10.1080/1744666X.2022.2054803] [Reference Citation Analysis]
30 Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia 2021;35:2616-20. [PMID: 33990684 DOI: 10.1038/s41375-021-01266-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
31 Anguiano-Álvarez VM, Maza-Larrea JA, Rosado-Hernández FJ, Rojas-Velasco G, Izaguirre-Ávila R. Ruxolitinib-induced extreme thrombocytosis in a COVID-19 patient. Blood Res 2021;56:201-2. [PMID: 34400588 DOI: 10.5045/br.2021.2020245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Li C, Zhao H, Cheng L, Wang B. Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19. Drug Des Devel Ther 2021;15:1345-56. [PMID: 33824579 DOI: 10.2147/DDDT.S301173] [Reference Citation Analysis]
33 Tascioglu D, Akkaya E, Genc S. The understanding of the immunopathology in COVID-19 infection. Scand J Clin Lab Invest 2021;81:255-63. [PMID: 34032527 DOI: 10.1080/00365513.2021.1892817] [Reference Citation Analysis]
34 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
35 Chen MR, Kuo HC, Lee YJ, Chi H, Li SC, Lee HC, Yang KD. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Front Immunol 2021;12:632890. [PMID: 33732254 DOI: 10.3389/fimmu.2021.632890] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
36 Magro CM, Mulvey J, Kubiak J, Mikhail S, Suster D, Crowson AN, Laurence J, Nuovo G. Severe COVID-19: A multifaceted viral vasculopathy syndrome. Ann Diagn Pathol 2021;50:151645. [PMID: 33248385 DOI: 10.1016/j.anndiagpath.2020.151645] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
37 Napolitano F, Di Spigna G, Vargas M, Iacovazzo C, Pinchera B, Spalletti Cernia D, Ricciardone M, Covelli B, Servillo G, Gentile I, Postiglione L, Montuori N. Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients. J Clin Med 2021;10:4914. [PMID: 34768433 DOI: 10.3390/jcm10214914] [Reference Citation Analysis]
38 Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One 2021;16:e0261113. [PMID: 34928990 DOI: 10.1371/journal.pone.0261113] [Reference Citation Analysis]
39 Titanji BK, Farley MM, Schinazi RF, Marconi VC. Response to Correspondence: Baricitinib - Impact on COVID-19 Coagulopathy? Jorgensen et. al. Clin Infect Dis 2020:ciaa1210. [PMID: 32797226 DOI: 10.1093/cid/ciaa1210] [Reference Citation Analysis]
40 Noris M. The case of complement inhibitors. Adv Biol Regul 2021;81:100822. [PMID: 34454870 DOI: 10.1016/j.jbior.2021.100822] [Reference Citation Analysis]
41 Lo MW, Kemper C, Woodruff TM. COVID-19: Complement, Coagulation, and Collateral Damage. J Immunol 2020;205:1488-95. [PMID: 32699160 DOI: 10.4049/jimmunol.2000644] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 22.0] [Reference Citation Analysis]
42 Mishra R, Behera LM, Rana S. Binding of raloxifene to human complement fragment 5a (hC5a): a perspective on cytokine storm and COVID19. J Biomol Struct Dyn 2020;:1-13. [PMID: 32930050 DOI: 10.1080/07391102.2020.1820381] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Li J, Liu B. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine Growth Factor Rev 2021;58:75-81. [PMID: 33558131 DOI: 10.1016/j.cytogfr.2020.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Kumar D, Trivedi N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomed Pharmacother 2021;139:111642. [PMID: 33940506 DOI: 10.1016/j.biopha.2021.111642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
45 Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulos MA. Emerging treatment strategies for COVID-19 infection. Clin Exp Med 2021;21:167-79. [PMID: 33128197 DOI: 10.1007/s10238-020-00671-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
46 Hasselbalch HC, Skov V, Kjær L, Ellervik C, Poulsen A, Poulsen TD, Nielsen CH. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev 2021;60:28-45. [PMID: 33992887 DOI: 10.1016/j.cytogfr.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, Zappetti D, Horn EM, Magro CM. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol 2020;219:108555. [PMID: 32771488 DOI: 10.1016/j.clim.2020.108555] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 23.0] [Reference Citation Analysis]
48 Annane D, Heming N, Grimaldi-Bensouda L, Frémeaux-Bacchi V, Vigan M, Roux AL, Marchal A, Michelon H, Rottman M, Moine P; Garches COVID 19 Collaborative Group. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine 2020;28:100590. [PMID: 33173853 DOI: 10.1016/j.eclinm.2020.100590] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
49 Pagliano P, Sellitto C, Conti V, Ascione T, Esposito S. Characteristics of viral pneumonia in the COVID-19 era: an update. Infection 2021;49:607-16. [PMID: 33782861 DOI: 10.1007/s15010-021-01603-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Yang B, Yang KD. Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention. Front Immunol 2021;12:690976. [PMID: 34335596 DOI: 10.3389/fimmu.2021.690976] [Reference Citation Analysis]
51 Siminea N, Popescu V, Sanchez Martin JA, Florea D, Gavril G, Gheorghe AM, Iţcuş C, Kanhaiya K, Pacioglu O, Popa IL, Trandafir R, Tusa MI, Sidoroff M, Păun M, Czeizler E, Păun A, Petre I. Network analytics for drug repurposing in COVID-19. Brief Bioinform 2021:bbab490. [PMID: 34864885 DOI: 10.1093/bib/bbab490] [Reference Citation Analysis]
52 Ortiz A. Complement and protection from tissue injury in COVID-19. Clin Kidney J 2020;13:734-8. [PMID: 33123353 DOI: 10.1093/ckj/sfaa196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Bonam SR, Kotla NG, Bohara RA, Rochev Y, Webster TJ, Bayry J. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today 2021;36:101051. [PMID: 33519949 DOI: 10.1016/j.nantod.2020.101051] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
54 Spinelli FR, Meylan F, O'Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol 2021;51:1615-27. [PMID: 33930196 DOI: 10.1002/eji.202048922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Limen RY, Sedono R, Sugiarto A, Hariyanto TI. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther 2021;:1-10. [PMID: 34538216 DOI: 10.1080/14787210.2021.1982695] [Reference Citation Analysis]
56 Quiros JR, Ross-Comptis J, Hathaway D 3rd, Sarfraz A, Sarfraz Z, Grigoryan Z, Romero KA, Gapizov A, Príncipe-Meneses FS, Somagutta MR, Riva-Moscoso A, Kapasi A. Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis. Infect Chemother 2021;53:436-48. [PMID: 34623777 DOI: 10.3947/ic.2020.0126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Dela Cruz CS, Sharma L. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infect Dis 2021;21:47. [PMID: 33430799 DOI: 10.1186/s12879-020-05730-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
58 Figueiredo DLA, Ximenez JPB, Seiva FRF, Panis C, Bezerra RDS, Ferrasa A, Cecchini AL, Medeiros AI, Almeida AMF, Ramão A, Boldt ABW, Moya CF, Chin CM, Paula D, Rech D, Gradia DF, Malheiros D, Venturini D, Tavares ER, Carraro E, Ribeiro EMSF, Pereira EM, Tuon FF, Follador FAC, Fernandes GSA, Volpato H, Cólus IMS, Oliveira JC, Rodrigues JHDS, Santos JLD, Visentainer JEL, Brandi JC, Serpeloni JM, Bonini JS, Oliveira KB, Fiorentin K, Lucio LC, Faccin-Galhardi LC, Ferreto LED, Lioni LMY, Consolaro MEL, Vicari MR, Arbex MA, Pileggi M, Watanabe MAE, Costa MAR, Giannini MJSM, Amarante MK, Khalil NM, Lima Neto QA, Herai RH, Guembarovski RL, Shinsato RN, Mainardes RM, Giuliatti S, Yamada-Ogatta SF, Gerber VKQ, Pavanelli WR, Silva WCD, Petzl-Erler ML, Valente V, Soares CP, Cavalli LR, Silva WA Jr. COVID-19: The question of genetic diversity and therapeutic intervention approaches. Genet Mol Biol 2021;44:e20200452. [PMID: 35421211 DOI: 10.1590/1678-4685-GMB-2020-0452] [Reference Citation Analysis]
59 Senent Y, Inogés S, López-Díaz de Cerio A, Blanco A, Campo A, Carmona-Torre F, Sunsundegui P, González-Martín A, Ajona D, Okrój M, Prósper F, Pio R, Yuste JR, Tavira B. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge. Front Immunol 2021;12:767376. [PMID: 34868021 DOI: 10.3389/fimmu.2021.767376] [Reference Citation Analysis]
60 Frankel AE, Reddy R, DeSuza KR, Deeb K, Carlin AF, Smith D, Xie Y, Naik E, Silver RT, Hasselbalch HC. Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib. Clin Case Rep 2021;9:2228-35. [PMID: 33936671 DOI: 10.1002/ccr3.3997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
61 Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Dela Cruz CS, Sharma L. Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis. medRxiv 2020:2020. [PMID: 32817985 DOI: 10.1101/2020.08.10.20172189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
62 Valentina G, Amelia F, Carmine S. Can we turn off the "Covid-biting-tail" inflammation? Transl Med UniSa 2020;23:39-41. [PMID: 34447711 DOI: 10.37825/2239-9747.1006] [Reference Citation Analysis]
63 Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches.Signal Transduct Target Ther. 2020;5:293. [PMID: 33361764 DOI: 10.1038/s41392-020-00454-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 27.5] [Reference Citation Analysis]
64 Sinkovits G, Mező B, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. Front Immunol 2021;12:663187. [PMID: 33841446 DOI: 10.3389/fimmu.2021.663187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]